CDK4/6 Combo Better Than Chemo in Advanced Breast Cancer CDK4/6 Combo Better Than Chemo in Advanced Breast Cancer

A new study confirms that a CDK4/6 blocker plus endocrine therapy is better than chemotherapy in young women with HR+, HER2- metastatic disease.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Related Links:

We reported nodal and breast downstaging rates with NET, and compared axillary response rates following NET and neoadjuvant chemotherapy (NAC).MethodsConsecutive stage I –III breast cancer patients treated with NET and surgery from January 2009 to December 2019 were identified from a prospectively maintained database. Nodal pCR rates were compared between biopsy-proven node-positive patients treated with NET, and HR+/HER2- patients treated with NAC from November 2 013 to July 2019.Results127 cancers treated with NET and 338 with NAC were included. NET recipients were older, more likely to have lobular and lower-grade...
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
Background: In PALOMA-3, endocrine therapy (ET)-sensitive (ie, documented clinical benefit from prior ET or 2 y adjuvant ET before recurrence) pts with HR+/HER2 – ABC and disease progression on prior ET derived overall survival (OS) benefit from palbociclib (PAL) + fulvestrant (FUL) vs placebo (PBO)+FUL. In pts who received prior chemotherapy (CT) for ABC, median (m)OS was similar between treatment arms, suggesting that prior CT impacts the benefit of PAL +FUL. This post hoc analysis reports OS and progression-free survival (PFS) in the ITT and ET-sensitive populations from PALOMA-3 with/without prior CT for ABC and ...
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: PROFFERED PAPER SESSION: Proffered Paper Session Source Type: research
Conclusions: Patients with metastatic breast cancer should perform re-biopsy to clarify the receptor status of the first metastatic lesions, which may provide clinicians valuable evidence to conduct treatments with higher precision.Oncol Res Treat
Source: Oncology Research and Treatment - Category: Cancer & Oncology Source Type: research
Authors: Zhang L, Zhang J, Li Z, Wu Y, Tong Z Abstract Bone is the most common site of metastatic spread in patients with breast cancer. Patients with bone-only metastasis (BOM) are a unique group. The aim of the present study was to compare the clinicopathological characteristics, survival and prognostic factors of patients with BOM and non-BOM. The clinical data of 1,290 patients with metastatic breast cancer treated at the Tianjin Medical University Cancer Institute and Hospital (Tianjin, China) between January 2008 and December 2017 were reviewed. The clinical data were divided into a BOM group (n=208 cases) an...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Tehrani OS Abstract Available data on systemic treatments in pregnancy-associated breast cancer (PABC) is reviewed in this section. These treatments include chemotherapy, endocrine therapy (ET), small molecule inhibitors, monoclonal antibodies against human epidermal growth factor receptor 2 (EGFR-2) also known as HER2; and human epidermal growth factor receptor 3 (EGFR-3), also known as HER3.In local disease, systemic treatment can be delivered as neoadjuvant (before surgery) or adjuvant (after surgery) treatment. In metastatic disease, systemic therapy is the main modality of treatment.Approach to PABC i...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
CONCLUSION: The increasing use of chemotherapy as patients progressed to second and later lines and the substantial direct/indirect economic burden underscore an unmet need. The high number of 1L regimens highlights significant heterogeneity and a lack of consensus related to the management of HR+/HER2- MBC in routine practice. PMID: 32755262 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
ConclusionsPalbociclib plus letrozole treatment led to a numerical but not statistically significant improvement in median OS.Pfizer Inc (NCT00721409)
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Abstract Breast cancer is the most common malignant tumor affecting women worldwide and is divided into the following subtypes: Luminal A, Luminal B, HER‑2 overexpression and triple‑negative breast cancer (TNBC). TNBC accounts for approximately 15‑20% of all breast cancer cases. Due to the characteristics of low differentiation, the likelyhood of recurrence and metastasis, strong invasiveness and the lack of hormone receptors and human epidermal growth factor receptor 2 (HER2), patients with TNBC cannot benefit from endocrine therapy or other available targeted agents. Chemotherapy is one...
Source: International Journal of Oncology - Category: Cancer & Oncology Authors: Tags: Int J Oncol Source Type: research
Conclusion: Our prodrug-based co-delivery system may provide an effective and simple strategy to re-sensitize TNBCs to TAM-based hormone therapy.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Abstract BACKGROUND: The integration of residual cancer burden (RCB) and post-treatment Ki67 as residual proliferative cancer burden (RPCB) has been proposed as a stronger predictor of long-term outcome in unselected patients with breast cancer (BC) undergoing neoadjuvant chemotherapy (NACT), as compared with RCB. However, no specific analysis in hormone-receptor-positive (HR+) human epidermal growth receptor 2-negative (HER2-) BC is available so far. MATERIALS AND METHODS: A cohort of 130 patients with HR + HER2- BC who underwent NACT between 2000 and 2014 was included. Archival surgical specimens ...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Endocrine Therapy | Health | Hematology | HER2 | Study | Women